Dimethylbenzylcarbinyl Acetate

We are Dimethylbenzylcarbinyl Acetate CAS:151-05-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:    Dimethylbenzylcarbinyl Acetate
CAS.NO:151-05-3
Synonyms:
Acetic Acid 1,1-Dimethyl-2-phenylethyl Ester
Acetic Acid α,α-Dimethylphenethyl Ester
(2-methyl-1-phenylpropan-2-yl) acetate
α,α-Dimethylphenethyl Acetate
1,1-Dimethyl-2-phenylethyl Acetate
Dimethylbenzylcarbinyl acetate

Molecular Formula: C12H16O2
Molecular Weight:192.25400

Physical and Chemical Properties:
Density: 0.998 g / mL at 25 ° C (lit.)
Boiling point: 250 ° C (lit.)
Melting point: /
Flash point: 206 ° F
Refractive index: n20 / D 1.4925 (lit.)

Specification:
Appearance: White to pale yellow crystalline powder
Purity:≥99%
Water:≤0.5%
Residue on ignition:≤0.2%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Fexofenadine hydrochloride CAS:138452-21-8
Intermediates of Fexofenadine CAS:83799-24-0

Related News: Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm.513-44-0 Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%.(R)-(3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl methanesulfonate CAS:174649-09-3 Therefore, the R & D capabilities and registration capabilities of API companies have become the core factors of competition.Ácido tioacético CAS:507-09-5 Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion.